Eyegate Pharmaceuticals (NASDAQ:EYEG) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Eyegate Pharmaceuticals in a research report on Thursday, November 9th.
Eyegate Pharmaceuticals (EYEG) opened at $1.03 on Friday. Eyegate Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $3.90. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.01.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last issued its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, hitting analysts’ consensus estimates of ($0.24). Eyegate Pharmaceuticals had a negative net margin of 2,480.28% and a negative return on equity of 1,494.75%. analysts forecast that Eyegate Pharmaceuticals will post -1.01 EPS for the current fiscal year.
A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. lifted its position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 247,319 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,988 shares during the period. Vanguard Group Inc. owned 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.95% of the company’s stock.
WARNING: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/04/eyegate-pharmaceuticals-eyeg-rating-increased-to-sell-at-valuengine.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.